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Abstract
Background: Delivery of two doses of intermittent preventive treatment of malaria during pregnancy (IPTp) is a key
strategy to reduce the burden of malaria in pregnancy in sub-Saharan Africa. However, different settings have reported
coverage levels well below the target 80%. Antenatal implementation guidelines in Tanzania recommend IPTp first dose
to be given at the second antenatal visit, and second dose at the third visit. This investigation measured coverage of IPTp
at national level in Tanzania and examined the role of individual, facility, and policy level influences on achieved coverage.
Methods: Three national household and linked reproductive and child health (RCH) facility surveys were conducted
July-August 2005, 2006, and 2007 in 210 clusters sampled using two-stage cluster sampling from 21 randomly selected
districts. Female residents who reported a livebirth in the previous year were asked questions about malaria prevention
during that pregnancy and individual characteristics including education, pregnancy history, and marital status. The RCH
facility serving each cluster was also surveyed, and information collected about drug stocks, health education delivery,
and the timing of antenatal care delivery by clinic users.
Results: The national IPTp coverage had declined over the survey period being 71% for first dose in 2005 falling to 65%
in 2007 (χ2 2.9, p = 0.05), and 38% for second dose in 2005 but 30% in 2007 (χ2 4.4, p = 0.01). There was no evidence
of any individual factors being associated with second dose coverage beyond living in an urban area. Availability of
sulphadoxine-pyrimethamine at RCH had decreased year on year from 85% of clinics in stock in 2005 to 60% in 2007 (χ2
20.6, p < 0.001). This reduction was evident in rural but not urban clinics. If safety recommendations and national
antenatal care guidelines for IPTp delivery were followed, in 2007 only 76% of pregnant women could have received IPTp
first dose and only 46% could have received second dose.
Conclusion: There is scope to improve IPTp first and second dose coverage at national scale within existing systems
by improving stock at RCH, and by revising the existing guidelines to recommend delivery of IPTp after quickening, rather
than at a pre-defined antenatal visit.
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Background
Over the last decade a number of reviews have firmly
established the burden of malaria in pregnancy as a prior-
ity public health issue [1-4]. One intervention widely pro-
moted to tackle this burden in malaria endemic areas in
sub-Saharan Africa is intermittent preventive treatment
for pregnant women (IPTp) [5,6].
With few exceptions, the implementation of IPTp has
been integrated within the existing antenatal care struc-
ture as part of the WHO recommended focused antenatal
care schedule [7]. The regime consists of the administra-
tion of two or three complete curative doses of an anti-
malarial medicine, the first after quickening – early in the
second trimester – and subsequent doses at monthly
intervals [8]. There is increasing awareness of the impor-
tance of administering at least two doses for a protective
effect [9-12]. Currently, sulphadoxine-pyrimethamine
(SP) is the recommended IPTp drug in several African
countries although, in light of increasing malaria parasite
resistance to SP, alternative drugs are under investigation
[13,14].
It is estimated that 80% of women across sub-Saharan
Africa access antenatal clinic at least once during preg-
nancy, and 74% at least twice [15]. SP is a relatively cheap
drug, has been widely available, and is amenable to
directly observed therapy requiring only a single dose for
each treatment. In theory, therefore, IPTp coverage using
SP should be high. However, as reported from many set-
tings [16-21] second dose coverage has been disappoint-
ing, with one exception [22], and there is concern that the
effectiveness of IPTp under programme conditions may
be much reduced [23]. There is an urgent need to under-
stand how the potential of this strategy can be realized.
Using national level linked household and facility data in
Tanzania collected annually over the period 2005–2007,
trends in IPTp coverage at a national scale are investigated,
and the influence of individual, facility and policy level
indicators on second dose IPTp coverage countrywide
explored.
Methods
Study setting
The mainland of the United Republic of Tanzania, which
excludes Zanzibar, has 133 districts across 21 regions and
a population of over 33 million people. It is a country
with high fertility and good access to antenatal care with
over 95% of women having at least two antenatal visits
[24]. The country is highly endemic for malaria and IPTp
has been implemented as national policy for the last five
years. The antenatal implementation schedule offers SP to
all pregnant women attending antenatal clinics at their
second visit between 20 and 24 weeks gestation for the
first dose and at their third visit between 28 and 32 weeks
for the second dose [25].
Study design
This investigation uses data collected as part of the Tanza-
nian National Voucher Scheme (TNVS) monitoring and
evaluation conducted in July-August of 2005, 2006 and
2007, full details of which, including survey instruments
used, are available elsewhere [26]. Three data sources are
analysed: household surveys, reproductive and child
health (RCH) facility surveys, and RCH user surveys.
(1) Household surveys were conducted in the same ran-
domly selected 21 districts across mainland Tanzania in
July/August each year with a two-stage cluster sample
design. Ten clusters (wards) were selected with probability
proportional to population size within each district. For
each cluster a sub-village (kitongoji) was sampled with
simple random sampling. Finally, 30 households were
sampled from each cluster using a EPI sampling approach.
At each household, interviews were conducted in Kiswa-
hili with the household head, with all women aged 15–49
and with all caregivers of children under five. An addi-
tional interview schedule was applied for women aged
15–49 who were currently pregnant, or who had had a
live birth in the preceding year. These data are used to pro-
vide estimates on IPTp coverage and individual level
influences.
(2) The RCH facility serving each cluster (described
above) was selected for survey. At each facility, equipment
and supplies were checked, staff and services provided
recorded, health education sessions observed, and a
review of routine antenatal record keeping was conducted.
These data are used to explore the facility level character-
istics influencing IPTp coverage estimates.
(3) At each RCH facility, up to a maximum of 7 women
who accessed antenatal care on the day of survey were
invited to be interviewed. The interview schedule
included questions about timing of attendance to RCH
throughout pregnancy, the timing of intervention deliv-
ery, and knowledge of specific aspects of malaria and
reproductive health. These data are used to explore the
policy level (specifically timing) characteristics influenc-
ing IPTp coverage estimates.
Data analysis and definitions
IPTp coverage was measured in the household survey. The
definition applied was in line with that recommended by
Roll Back Malaria [27]: "The proportion of all women sur-
veyed who had a live birth in the last year who reported
having received one (or at least two where stated) doses of
IPTp during their last pregnancy."Malaria Journal 2008, 7:260 http://www.malariajournal.com/content/7/1/260
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The residential status of households is defined at the Ward
level from the 2002 Tanzanian National Census, grouped
as urban and non-urban (rural/semi-urban).
The socio-economic status of households relative to each
other is grouped by quintile, quintile 1 being most poor.
This was derived from principal components analysis
using a combination of variables including household
head education level, housing conditions, asset owner-
ship of household and whether the house was rented or
not.
All estimates were adjusted for cluster sampling using svy
commands in STATA 10. The χ2 test was used to examine
differences in IPTp coverage by explanatory variables
within survey years, and to examine differences in IPTp
coverage levels across survey years. A summary of
respondents from the household and facility surveys
included in this analysis is given in Table 1.
Ethical approval
The monitoring and evaluation protocol was approved by
the ethical review committee at London School of
Hygiene and Tropical Medicine, UK, and by the Institu-
tional Review Board at Ifakara Health Institute, Tanzania.
The purpose and potential risks arising from participation
were explained to all sampled persons, and anonymity
was assured. Each interviewee was asked to provide writ-
ten consent.
Results
Individual level characteristics
Coverage of IPTp across time
Estimates for both first and second dose coverage of IPTp
have declined over the period from 71% (836/1,171) in
2005 to 65% (791/1,214) in 2007 reporting first dose (χ2
2.9, p = 0.05) and 38% (443/1,171) in 2005 to 31% (370/
1,214) in 2007 (χ2 4.4, p0.01) reporting second dose
(Table 2).
Coverage of IPTp by individual characteristics
Coverage was disaggregated for 2007 by the individual
level characteristics of age, marital status, education level
of the woman, household socio-economic status and res-
idence (Table 2). Residence was highlighted as an impor-
tant differential for IPTp first and second dose estimates,
coverage being higher amongst women in urban than
women in non-urban settings for first dose: 78% (74/95)
compared to 64% (718/1119), χ2 4.8 (p = 0.02) and for
second dose: 44% (42/95) urban compared to 29% (329/
1119) non-urban, χ2 5.1(p = 0.02). There was evidence to
suggest that women with education levels beyond com-
pleted primary, and more wealthy women, were more suc-
cessful than other women in getting a first dose of IPTp
but this was not true for second dose (Table 2).
Reasons for not taking IPTp
Women who reported attending an antenatal clinic when
they were pregnant, who said they had not received the
first dose of IPTp, were asked why they had not. Over 90%
reported that they had not been asked whether they
wanted it, with a slight increase in the percent not asked
by survey year: 2005: 92.0% (307/334), 2006: 92.5%
(355/384), and 2007: 96.2% (406/422) (χ2 2.8, p0.06).
This finding does not appear to be linked to individual
status for any of the survey years, with no difference in the
percent not asked by socio-economic quintile (χ2 2.0,
p0.7), age (χ2 4.0, p0.5), education (χ2 2.2, p0.5) or by
residence (χ2 0.3, p0.8) of the woman in 2007.
Facility level characteristics
Stock of sulphadoxine/pyrimethamine at antenatal clinic
There was a decline in the number of RCH facilities with
SP in stock on the day of the survey from 85% (161/190)
in 2005 to 59% (78/192) in 2007 (χ2 20.6, p < 0.001)
across all levels of clinics (Table 3). This aggregate figure
was dominated by declines in rural clinics from 84%
(105/125) in 2005 to 55% (73/133) in 2007 (χ2 16.5, p <
0.001), but there was no difference in urban clinics, being
86% (19/22) in 2005 and 88% (15/17) in 2007 (χ2 1.1 (p
= 0.2).
Table 1: Respondents to Household, RCH facility and RCH facility user surveys, Tanzanian National Voucher Scheme 2005–2007
Year 2005 2006 2007
TNVS Annual Survey Sample
N. Districts 21 21 21
N. Clusters 210 210 210
Household Survey
N. Households 6199 6260 6198
N. Women with a live birth in previous 12 months 1171 1229 1214
RCH facility survey
N. Clinics 190 188 192
N. Clinics providing outreach services 108 100 122
N. RCH facility user interviews 848 862 914Malaria Journal 2008, 7:260 http://www.malariajournal.com/content/7/1/260
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This cross-sectional data reports on stock on the day of
survey but not duration of stock-out. However, by linking
the coverage estimates derived from RCH facility user
interviews with the stock in the facility that day we are
able to demonstrate the impact of stock-outs on access. In
2007, first dose IPTp coverage was only 41% (49/121)
amongst women accessing a facility experiencing a SP
stock-out, compared to 89% (164/184) amongst women
accessing a facility with SP stock that day (χ2 54.3 (<
0.001).
Visual aides for IPTp
Not only was there a significant decline in SP stocks at
RCH facilities but there was also a decline in the percent
of facilities displaying posters explaining the purpose and
benefits of IPTp from 70% (134/190) in 2005 to 50%
(96/191) in 2007 (χ2 11.5, p < 0.001).
IPTp at outreach clinic
Around 60% of RCH clinics reported providing an out-
reach antenatal service to women in remote areas (Table
1). A decline was observed in the percent of facilities
administering IPTp at outreach clinic from 63% (68/108)
in 2005 to 45% 55/122 in 2007 (χ2 6.5, p0.001).
Health education
Health education sessions were observed in 54% (111/
190) of facilities in 2005, 67% (126/188) in 2006 and
62% (118/191) in 2007. A check list was used to indicate
which topics were mentioned during the observed ses-
sion. Just under half of all sessions delivered malaria pre-
vention messages, with no difference by year: 47% in
2005, 43% in 2006 and 46% in 2007 (χ2 0.2, p0.8).
In 2006, as part of the RCH facility antenatal user inter-
view, an exploration was made into pregnant women's
understanding of malaria prevention options. 66% (571/
862) were unable to answer the question "How many
times should you take the medicine to prevent malaria
during pregnancy?" and a further 6% (49/862) answered
only one dose.
Table 2: Percent of women reporting that they received first or second dose of an anti-malarial drug as intermittent preventive 
treatment (IPTp) at RCH facilities in Tanzania, TNVS Household survey 2005–2007
First dose
% (95% CI)
χ2
(p-value)
Second dose
% (95% CI)
χ2
(p-value)
For three survey years:
TNVS Household survey 2005 [N = 1171] 71.4 (67.8–74.7) 37.8 (34.3–41.5)
TNVS Household survey 2006 [N = 1229] 68.6 (65.1–71.9) 35.2 (31.7–38.9)
TNVS Household survey 2007 [N = 1214] 65.2 (61.3–68.9) 2.9 (0.05) 30.5 (27.2–34.2) 4.4 (0.01)
For 2007 only:
Residence
Urban [N = 95] 77.8 (66.1–86.4) 44.2 (31.7–57.4)
Non-urban [N = 1119] 64.2 (60.0–68.1) 4.8 (0.02) 29.4 (22.9–33.1) 5.1 (0.02)
Education level
No education [N = 298] 54.7 (48.4–60.8) 26.8 (21.2–33.3)
Incomplete primary [N = 147] 59.2 (51.4–66.5) 29.9 (23.4–37.4)
Complete primary [N = 728] 69.9 (65.6–73.9) 31.6 (27.6–35.9)
Secondary + [N = 41] 80.5 (65.1–90.1) 10.2( < 0.01) 41.5 (25.6–59.2) 1.3 (0.2)
Marital Status
Married/co-habit [N = 1005] 64.4 (59.9–68.5) 30.5 (27.0–34.3)
Previously married [N = 101] 72.3 (62.4–80.4) 34.6 (26.4–43.9)
Never married [N = 108] 66.7 (56.2–75.7) 1.1 (0.3) 26.8 (18.3–37.6) 0.7 (0.4)
Age
< 20 years [N = 149] 62.4 (53.9–70.2) 29.5 (22.6–37.5)
20–24 [N = 316] 65.2 (58.9–70.9) 32.9 (27.1–39.3)
25–29 [N = 279] 68.4 (61.8–74.4) 32.3 (26.3–38.9)
30–34 [N = 238] 64.3 (57.0–70.9) 30.2 (24.6–36.5)
35–39 [N = 147] 63.3 (54.6–71.1) 30.5 (20.3–43.2)
40+ [N = 72] 72.2 (58.9–82.5) 0.6 (0.6) 25.8 (18.9–34.3) 0.5 (0.7)
Socio-economic status
Q1 (Most poor) [N = 208] 55.3 (47.7–62.6) 26.9 (20.9–33.8)
Q2 [N = 291] 60.5 (53.6–66.9) 26.8 (21.4–32.9)
Q3 [N = 244] 67.2 (60.6–73.2) 31.1 (24.7–38.3)
Q4 [N = 255] 67.4 (61.2–73.1) 32.5 (26.8–38.8)
Q5 (Least poor) [N = 371] 76.7 (69.5–82.6) 5.9 (< 0.01) 36.3 (28.9–44.4) 1.5 (0.18)Malaria Journal 2008, 7:260 http://www.malariajournal.com/content/7/1/260
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Table 3: Stock of sulphadoxine pyrimethamine on the day of survey, TNVS RCH Facility Survey 2005–07
2005 2006 2007 χ2 (p-value)1
All 84.7 (78.8–89.2)
[N = 190]
74.5 (67.7–80.2)
[N = 188]
59.5 (52.2–66.1)
[N = 192]
20.6 (< 0.001)
By level of facility
Dispensary 84.7 (77.9–89.6)
[N = 150]
71.3 (63.1–78.3)
[N = 136]
55.6 (47.3–63.5)
[N = 144]
19.3 (< 0.001)
Health Centre 95.2 (72.5–99.3)
[N = 21]
80.6 (62.9–91.1)
[N = 31]
72.4 (53.6–85.6)
[N = 29]
3.2 (0.04)
Hospital 73.7 (50.0–88.7)
[N = 19]
85.7 (63.6–95.3)
[N = 21]
68.4 (44.9–85.2)
[N = 19]
0.9 (0.3)
χ2 (p-value)2 1.7 (0.1) 1.3 (0.2) 1.7 (0.1)
By residence
Rural 84.0 (76.4–89.5)
[N = 125]
72.3 (63.9–79.4)
[N = 130]
54.9 (46.3–63.2)
[N = 133]
16.5 (< 0.001)
S-Urban 86.0 (72.1–93.6)
[N = 43]
70.7 (55.0–82.6)
[N = 41]
61.9 (46.4–75.3)
[N = 42]
3.5 (0.03)
Urban 86.4 (64.9–95.6)
[N = 22]
100
[N = 17]
88.2 (62.9–97.1)
[N = 17]
1.2 (0.2)
χ2 (p-value)2 0.07 (0.9) 3.3 (0.03) 3.5 (0.03)
χ2 (p-value)1 for difference between survey years
χ2 (p-value)2 for difference within survey years
Distribution of antenatal attendance < 20 weeks (too early IPTp), 20–32 weeks (recommended IPTp) and > 32 weeks (too late  IPTp) gestation at first, second and third antenatal visits to RCH facility, TNVS RCH facility survey, 2007 Figure 1
Distribution of antenatal attendance < 20 weeks (too early IPTp), 20–32 weeks (recommended IPTp) and > 32 weeks (too late 
IPTp) gestation at first, second and third antenatal visits to RCH facility, TNVS RCH facility survey, 2007.Malaria Journal 2008, 7:260 http://www.malariajournal.com/content/7/1/260
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Policy level
IPT schedule for delivery
Pregnant women in Tanzania are recommended to first
attend antenatal clinic by 16 weeks gestation, their second
visit to take place around 20 weeks, and third around 28
weeks. In this population however (and typical of sub-
Saharan Africa) the median gestation at first visit was 20
weeks and the median gestation at second visit was 26
weeks. In reality, therefore, women attend clinic later than
recommended antenatal policy and this is found to dis-
rupt the antenatal schedule for delivery of IPTp which rec-
ommends delivery of IPTp first dose at the second
antenatal visit.
In Figure 1, the gestation of women at first, second, and
third antenatal visit is grouped according to implication
for IPTp delivery (< 20 weeks: too early; 20–32 weeks: rec-
ommended; > 32 weeks: too late). At the first visit, 64% of
pregnant women were within the recommended gestation
to receive IPTp yet current policy recommends IPTp be
given at second visit, and potentially these women were
missed. At the second visit, 76% of pregnant women were
within the recommended gestation to receive IPTp in
accordance with policy. At the third visit, only 46% of
pregnant women were within the recommended gestation
to receive IPTp second dose in accordance with antenatal
policy. These figures are not dissimilar to the coverage
estimates of 65% and 31% for first and second dose
(Table 2).
Discussion
Across mainland Tanzania in 2007, 65% of women who
had a pregnancy in the previous year reported receiving
first dose of IPTp and 30% second dose. This national
level analysis of individual, facility and policy influences
on coverage has revealed that throughout the period
2005–2007 delivery of second dose was negatively influ-
enced by facility level factors, and probably policy related
factors in Tanzania, but not by the individual characteris-
tics of women beyond living in an urban area.
A lack of association between uptake of two doses of IPTp
and individual factors in Tanzania has been reported pre-
viously, right from the beginning of IPTp implementa-
tion. The Demographic and Health Survey conducted in
2004 – soon after nationwide IPTp implementation –
found no individual level association with IPTp second
dose, nor did a small-scale exploration during the same
time-period [24,28]. Our finding of 65% first dose and
30% second dose coverage shows some improvement on
the 2005 Demographic and Health Survey estimates, 53%
and 22% respectively, but remains far from the target of
80%.
This analysis uses responses following the lead question
"When you went to the clinic were you given the medicine
to prevent malaria?" Restricting the data to only those
women who could state the type of drug administered
considerably restricts the number of valid responses as
women frequently cannot state the drug used. However,
the only drug administered as IPTp during the study
period was SP. Observations from the facility survey sug-
gest that stock outs of SP had a dramatic effect on coverage
of the intervention. Previously the delivery of IPTp bene-
fited from using the same drug as the first-line anti-malar-
ial treatment drug, SP, and needed no separate delivery
system. It would appear that since the change over to co-
artemether lumifantrine in 2006, the mechanisms for
maintaining stocks of SP for IPTp require urgent atten-
tion, particularly in non-urban settings. It is worth men-
tioning here that facility user data is prone to responder
bias as participants tend to give more positive responses
than in population level household surveys and therefore
levels of coverage observed may not be comparable
between the two sources. However, the finding that cover-
age was at least 100% higher for women who attended a
clinic with SP in stock than women who attended a clinic
with no SP is likely a true reflection of the problem.
Less than half of health education sessions observed deliv-
ered malaria prevention messages. Such observations are
sometimes associated with a Hawthorne effect – that
workers observed for a short period of time tend to
improve performance – and so the reality may be lower.
The finding is surprising in Tanzania where there is clear
commitment to reducing the burden of malaria and a
number of initiatives have been designed to raise the pro-
file of malaria nationally. It is worthwhile to investigate
why these training and support initiatives are not translat-
ing into measurable delivery of clear malaria prevention
messages to clinic users.
The delivery of IPTp at outreach clinics was reported to
have declined during the period of the surveys. Again, this
finding is contrary to the strong national commitment to
control malaria. It is possible that this has arisen because
of drug shortages – with rationing of SP for clinic based
services taking place. Certainly barriers to delivery of IPTp
at outreach where the most remote and vulnerable
women are targeted should be addressed.
The schedule for delivery of IPTp has been scrutinized
over the last year in a number of settings [9,29-31]. The
Tanzanian antenatal policy of giving IPTp first dose at the
second antenatal visit and second dose at the third ante-
natal visit was developed in part for its simplicity, and to
minimize the burden placed on health staff from the
increasing number of interventions being channelled
through antenatal clinics. However, for high coverage toMalaria Journal 2008, 7:260 http://www.malariajournal.com/content/7/1/260
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be realized, this policy demands simultaneous behaviour
change from the pregnant woman population – to first
attend clinic earlier than the current median of 20 weeks
gestation – and from the facility worker – to implement
the schedule. A previous small scale study in Tanzania
found that facility workers do aim to stay within the rec-
ommendation for IPTp delivery, and reported missed
opportunities for protecting pregnant women with two
doses [16]. The Tanzanian antenatal guideline is critically
different from the current WHO recommendation to dis-
tribute SP to all pregnant women at the first visit after
quickening [8]. This is also designed to be an easily opera-
tionalized policy which stays within safety limits of SP in
pregnancy, and importantly is not dependent on individ-
ual timing preferences for first attendance to antenatal
clinic. It may be that the Tanzanian IPTp antenatal sched-
ule should be revised accordingly while there is no evi-
dence of behaviour change for earlier first attendance to
clinic.
Results from investigations on a smaller-scale in sub-
Saharan Africa have indicated a combination of lack of
awareness, health worker behaviour, stock-outs and pol-
icy as possible explanations for low recorded coverage of
IPTp [16,18-20,32]. Our national level analysis indicates
that, in Tanzania, successful delivery of at least two doses
of IPTp relies on facility and policy level factors that could
potentially be resolved. Following a trial of IPTp imple-
mentation in the community compared to routine clinics,
Mbonye and others [33] found that the community
approach resulted in higher – and earlier – two-dose cov-
erage than the routine approach. However, they caution
that it would be important to support access to routine
care where all other access to antenatal services was
focussed. In Zambia, where high coverage of IPTp second
dose has been achieved and sustained within existing sys-
tems, an analysis of enabling factors highlights co-ordi-
nated support to the routine clinic system and training to
antenatal care workers as key enabling factors [22].
Conclusion
Acting upon the observed rural stock outs and uninten-
tionally restrictive antenatal guidelines in Tanzania is the
most direct and sustainable option for optimising delivery
of IPTp with SP. The challenge posed to IPTp with SP by
increasing drug resistance of the Plasmodium falciparum
parasite is beyond the operational control of the health
system. Should a new drug for IPTp be recommended, the
obstacles to high coverage will undoubtedly persist. It is
essential that lessons are learned on how to maximize the
existing regime in order to avoid any backward step on the
road to 80% access.
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